Everything below concerns half-life. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
This enabled them to make a number of major technological improvements, including the introduction of fiber suppressors (1981), a metal-free system eliminating sources of contamination and corrosion (1981), integrated workstation and process analysis capabilities (1984), suppressors for gradient elution (1986) and accelerated solvent extraction (1995). These technological changes made it possible for scientists to detect ionic materials quickly at extremely low levels of concentration. This increased both the sensitivity of the tests that it was possible to do and the productivity of the people doing them. Bowman recognized the importance of developing software and data handling capabilities in support of Dionex's hardware. Bowman has also emphasized the importance of marketing support, working closely with customers to ensure that they were satisfied with the products they were using, and developing new applications for customers' areas of interest. He has stated that, in his opinion, what distinguished Dionex was that "we do provide a complete solutions approach for our customers. We don't just sell them hardware and walk away. We work with them to make sure that what we sell them makes them more effective and productive in their job." Through such improvements, Dionex was able to support much faster extraction of organic compounds for analysis from chemical mixtures, including complicated samples such as soils, polymers, and processed foods.
=== 20th century === During the 20th century, Harold Wolff's vascular theory linked migraine pain to the widening of blood vessels. Ergotamine, one of the principal alkaloids responsible for its antimigraine effects, was isolated from the ergot fungus in 1918. It was first used to treat migraine in 1925. Methysergide was developed in 1959. The first triptan, sumatriptan, was developed in 1988. Other discoveries identified serotonin as an important chemical involved in migraine, leading to the development of serotonin receptor agonists for treatment. Later, the discovery of calcitonin gene-related peptide (CGRP) improved understanding of migraine and led to the development of targeted CGRP-based medicines.
Chicks grow very quickly and are fully grown in five to six months; they may remain with their family group for another six months or so before they split up to breed in their second season. During their early life, the young emus are defended by their father, who adopts a belligerent stance towards other emus, including the mother. He does this by ruffling his feathers, emitting sharp grunts, and kicking his legs to drive off other animals. He can also bend his knees to crouch over smaller chicks to protect them. At night, he envelops his young with his feathers. As the young emus cannot travel far, the parents must choose an area with plentiful food in which to breed. In the wild, emus can live for upwards of 10 years but in captivity, they can live up to 20 years.
RCH2=CH2CO-CoA + NADPH + H+ The two substrates of this enzyme are an acyl-CoA and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are the corresponding 2,3-dehydroacyl-CoA, reduced NADPH, and a proton. The enzyme does not alter the length of the chain attached to coenzyme A but creates a double bond adjacent to the carbonyl group. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is acyl-CoA:NADP+ 2-oxidoreductase. Other names in common use include 2-enoyl-CoA reductase, dehydrogenase, acyl coenzyme A (nicotinamide adenine dinucleotide, phosphate), enoyl coenzyme A reductase, crotonyl coenzyme A reductase, crotonyl-CoA reductase, and acyl-CoA dehydrogenase (NADP+).
Sources: en.wikipedia.org
==== Eurasian plate ==== Eifel hotspot (8) 50°12′N 6°42′E, w= 1 az= 082° ±8° rate= 12 ±2 mm/yr Iceland hotspot (14) 64°24′N 17°18′W Eurasian Plate, w= 0.8 az= 075° ±10° rate= 5 ±3 mm/yr North American Plate, w= 0.8 az= 287° ±10° rate= 15 ±5 mm/yr Possibly related to the North Atlantic continental rifting (62 Ma), Greenland. Azores hotspot (1) 37°54′N 26°00′W Eurasian Plate, w= 0.5 az= 110° ±12° North American Plate, w= 0.3 az= 280° ±15° Jan Mayen hotspot (15) 71°00′N 9°00′W Hainan hotspot (46) 20°00′N 110°00′E, az= 000° ±15°
Immunoglobulin G (IgG) antibodies are large heterodimeric molecules, approximately 150 kDa and are composed of two kinds of polypeptide chain, called the heavy (~50kDa) and the light chain (~25kDa). The two types of light chains are kappa (κ) and lambda (λ). By cleavage with enzyme papain, the Fab (fragment-antigen binding) part can be separated from the Fc (fragment crystallizable region) part of the molecule. The Fab fragments contain the variable domains, which consist of three antibody hypervariable amino acid domains responsible for the antibody specificity embedded into constant regions. The four known IgG subclasses are involved in antibody-dependent cellular cytotoxicity. Antibodies are a key component of the adaptive immune response, playing a central role in both in the recognition of foreign antigens and the stimulation of an immune response to them. The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens presented on the surfaces of tumors. Monoclonal antibodies can be acquired in the immune system via passive immunity or active immunity. The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly. Additionally, adverse reactions from these antibodies may occur because of long-lasting response to antigens.
For example, the nitrile group of the competitive PDE-3 inhibitor milrinone forms an affinity-relevant hydrogen bond via a histidine residue located at the binding site of these phosphodiesterases. Nitriles can form a coordinative bond with calcium cations, which is essential for the activity of calcium antagonists of the verapamil type. These agents inhibit calcium influx by forming, through ligand–calcium complex chemistry, a salt bridge with one of the glutamic acid residues in the selectivity filter within the pore of the calcium channel. Verapamil is used in cardiovascular diseases such as arterial hypertension and angina pectoris. Nitrile substituents decrease the electron density of aromatic compounds through a strong inductive effect. In this manner, π-π interactions between a drug molecule and suitable amino acid residues of a target protein, such as phenylalanine, tyrosine, tryptophan, and histidine, are modulated. Such π-π interactions are observed with the aromatase inhibitors letrozole and anastrozole, which act as antiestrogens and are used in breast cancer. Many androgen receptor antagonists contain a markedly electron-deficient aromatic ring, which is particularly important for supramolecular receptor binding. In bicalutamide, enzalutamide, and other analogs used to treat prostate cancer, a nitrile group contributes to this electronic effect. In some cases, nitriles form a reversible yet pharmacologically relevant covalent bond with a target molecule.
== Affected areas == Many states are directly affected by the drug trade that occurs in the Indian Ocean region, both economically and socially. These detrimental effects are felt throughout many different countries, in a variety of ways, such as a possible increase in drug use by the populations and heightened levels of corruption.
== Discovery == Alexander von Humboldt is sometimes said to have been the first to report the first synthetic peroxide, barium peroxide, in 1799 as a by-product of his attempts to decompose air, although this is disputed due to von Humboldt's ambiguous wording. Nineteen years later Louis Jacques Thénard recognized that this compound could be used for the preparation of a previously unknown compound, which he described as eau oxygénée ("oxygenated water") — subsequently known as hydrogen peroxide. An improved version of Thénard's process used hydrochloric acid, followed by addition of sulfuric acid to precipitate the barium sulfate byproduct. This process was used from the end of the 19th century until the middle of the 20th century. The bleaching effect of peroxides and their salts on natural dyes had been known since Thénard's experiments in the 1820s, but early attempts of industrial production of peroxides failed. The first plant producing hydrogen peroxide was built in 1873 in Berlin. The discovery of the synthesis of hydrogen peroxide by electrolysis with sulfuric acid introduced the more efficient electrochemical method. It was first commercialized in 1908 in Weißenstein, Carinthia, Austria. The anthraquinone process, which is still used, was developed during the 1930s by the German chemical manufacturer IG Farben in Ludwigshafen.
Sources: en.wikipedia.org
Official website The Jesus and Mary Chain at AllMusic The Jesus and Mary Chain at IMDb 1985 audio interview on RPM Club Long article in The Guardian, 2014 The Making of Psychocandy, 2015 interview with Jim Reid The Jesus and Mary Chain's Psychocandy, 2016 article on The Literary Hub The Jesus And Mary Chain's Glasgow Eyes, 2024 interview with Jim Reid on Qobuz Magazine
== See also == Executive order List of executive actions by Barack Obama List of executive actions by Joe Biden List of executive orders in the second presidency of Donald Trump List of bills in the 119th United States Congress
== Further reading == Althouse BM, Hébert-Dufresne L (October 2014). "Epidemic cycles driven by host behaviour". Journal of the Royal Society, Interface. 11 (99) 20140575. doi:10.1098/rsif.2014.0575. PMC 4235258. PMID 25100316.
== History == Bottromycin was first isolated from Streptomyces bottropensis in 1957. It has since been identified in at least two other members of the genus Streptomyces; members of Streptomyces are known to be prolific producers of secondary metabolites. Bottromycin has a unique structure, consisting of the macrocyclic amidine linkage and four β-methylated amino acids. Bottromycin blocks aminoacyl tRNA binding to the ribosome by binding to the A site of the 50s subunit. Although bottromycin was discovered over 50 years ago, there was a lack of research following initial studies on bottromycin until recent years. The lack of research is potentially a result of bottromycin's low stability in blood plasma. However, the unique structure and mode of action have recently made bottromycin a more target for drug development, especially given the rise of antibiotic resistance.
=== Role in cancer progression and therapy resistance === ITGA1 contributes to tumor progression by regulating survival, migration, invasion, and resistance to anticancer therapies. In Pancreatic Ductal Adenocarcinoma (PDAC), ITGA1-mediated collagen EMT signaling promotes the survival of mesenchymal tumor cell populations, metastatic dissemination, and resistance to gemcitabine treatment. Inhibition of ITGA1 increases sensitivity to chemotherapy, making treatment more effective and supporting its capacity as a potential therapeutic target. In glioma, ITGA1 contributes to temozolomide (TMZ) resistance by activating the PI3K/AKT/Bcl-2 signaling pathway. Increased ITGA1 activity promotes anti-apoptotic signaling which prevents tumor cells from apoptosizing therefore leading to survival of tumor cells. Suppressing ITGA1 increases apoptosis and improves TMZ sensitivity. ITGA1 expression in glioma is regulated by the hsa-miR01298-5p pathway, which directly binds the ITGA1 3' untranslated region to suppress ITGA1 expression. Increased ITGA1 reverses those effects, making resistance to chemotherapy more likely.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.